Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Healx has experienced delays to the site activation of the study and this has had an adverse impact on the recruitment timeline which is delaying the progress of other projects in our FXS programme.

Conditions

Fragile X Syndrome

Interventions

DRUG: Sulindac (HLX-0201), dose strength 1
DRUG: Sulindac (HLX-0201), dose strength 2
DRUG: Placebo
DRUG: Gaboxadol (HLX-0206)

Sponsor

Healx Limited